Möchten Sie immer auf dem neuesten Stand bleiben?

ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with PNETs at ENETS 2026

ITM today announced that it will provide further post-hoc subgroup analysis data focusing on Pancreatic Neuroendocrine Tumors from its Phase 3 trial

Patent for composition of matter and methods of use of high-radiopure diagnostic ⁶¹Cu-NU101 and combination use with therapeutic pair ⁶⁷Cu-NU101

BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping...

Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine...

Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires...

Curium has established a legal entity in China which represents a major milestone in Curium’s international growth strategy and will enhance Curium’s ability to serve patients with cancer across...

Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shapeBrings over 15 years...

ITM Announces FDA NDA Acceptance and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in GEP-NETs

Ottawa, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceutical market size was valued at USD 6.8 billion in 2024 and is predicted to hit around USD 14.11 billion by 2034, rising at a 7.57%...